CAV1 and neoplasm: Collectively, these findings identify CAV1 as a central regulator of tumour dormancy-associated pathways and acquired TKI-resistance through modulation of E-cadherin, RAC1 and p21, alongside activation of the P70S6K and STAT3 pathways.